Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SINAPPS2: IVIG and rituximab in antibody-associated psychosis
ISRCTN11177045Phase 2Active, not recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of immune globulin and rituximab in autoimmune psychosis (AP) and psychosis (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Time to start of symptomatic remission sustained for 6 months. Started Oct 2017; status: active, not recruiting.
02
Drugs
immune globulinrituximab
03
Conditions
autoimmune psychosis (AP)psychosis
Beyond the preview
Go deeper on ISRCTN11177045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11177045.